MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

Home・Akciju saraksts・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

32.45 0.81

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

32.05

Max

32.73

Galvenie mērījumi
By Trading Economics
Ienākumi	-14M -81M
Pārdošana	75K 75K
EPS	-1.22
Peļņas marža	-108,422.667
Darbinieki	198
EBITDA	-7.8M -81M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+69.04% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 6. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	472M 2.1B
Iepriekšējā atvēršanas cena	31.64
Iepriekšējā slēgšanas cena	32.45

Ziņu noskaņojums

By Acuity

100%

330 / 348 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bullish Evidence

18.91 / 20.63 Atbalsts un pretestība

Celldex Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 13. apr. 23:25 UTC

Galvenie ziņu notikumi

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

2026. g. 13. apr. 22:45 UTC

Galvenie ziņu notikumi

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

2026. g. 13. apr. 18:03 UTC

Peļņas

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

2026. g. 13. apr. 23:58 UTC

Peļņas

Review & Preview: Earnings Time -- Barrons.com

2026. g. 13. apr. 23:49 UTC

Tirgus saruna

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

2026. g. 13. apr. 23:33 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Edges Higher Amid Dollar Weakness -- Market Talk

2026. g. 13. apr. 23:20 UTC

Tirgus saruna

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

2026. g. 13. apr. 23:01 UTC

Peļņas

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

2026. g. 13. apr. 23:01 UTC

Peļņas

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

2026. g. 13. apr. 23:01 UTC

Peļņas

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

2026. g. 13. apr. 22:21 UTC

Iegādes, apvienošanās, pārņemšana

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

2026. g. 13. apr. 21:53 UTC

Peļņas

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

2026. g. 13. apr. 21:53 UTC

Peļņas

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

2026. g. 13. apr. 21:53 UTC

Peļņas

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

2026. g. 13. apr. 21:53 UTC

Peļņas

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

2026. g. 13. apr. 21:26 UTC

Galvenie ziņu notikumi

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

2026. g. 13. apr. 21:23 UTC

Peļņas

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

2026. g. 13. apr. 21:16 UTC

Peļņas

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

2026. g. 13. apr. 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 13. apr. 20:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 13. apr. 20:34 UTC

Peļņas

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

2026. g. 13. apr. 20:34 UTC

Peļņas

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

2026. g. 13. apr. 20:34 UTC

Peļņas

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

2026. g. 13. apr. 19:59 UTC

Tirgus saruna

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

2026. g. 13. apr. 19:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

2026. g. 13. apr. 19:27 UTC

Tirgus saruna

Galvenie ziņu notikumi

Correction to Precious Metals Market Talk on April 9

2026. g. 13. apr. 19:14 UTC

Tirgus saruna

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

2026. g. 13. apr. 18:59 UTC

Tirgus saruna

Galvenie ziņu notikumi

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

2026. g. 13. apr. 18:59 UTC

Tirgus saruna

Galvenie ziņu notikumi

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

2026. g. 13. apr. 18:43 UTC

Tirgus saruna

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Salīdzinājums

Cenas izmaiņa

Celldex Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

69.04% augšup

Prognoze 12 mēnešiem

Vidējais 54.5 USD 69.04%

Augstākais 90 USD

Zemākais 24 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Celldex Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

11 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 11 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Celldex Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

18.91 / 20.63Atbalsts un pretestība

Recent bullish events outweigh bearish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.